PDSB PDS Biotechnology
- 3.260
- +0.010+0.31%
- 3.170
- -0.090-2.76%
PDS Biotechnology News
PDS Biotechnology Analyst Ratings
Noble Financial Sticks to Its Buy Rating for PDS Biotechnology (PDSB)
B. Riley Securities Adjusts PDS Biotechnology's Price Target to $11 From $14, Maintains Buy Rating
PDS Biotechnology Analyst Ratings
PDS Biotechnology (PDSB) Gets a Buy From Noble Financial
PDS Biotechnology Analyst Ratings
Oppenheimer Adjusts PDS Biotechnology Price Target to $20 From $23, Maintains Outperform Rating
Mayank Mamtani Assigns Buy Rating to PDS Biotechnology: Impressive Outcomes From Phase II Trial and Promising Future Prospects
Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB) and Shattuck Labs (STTK)
HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target
PDS Biotechnology Analyst Ratings
Promising Clinical Trial Results and Undervalued Potential Bolster Buy Rating for PDS Biotechnology: An Analysis
PDS Biotechnology (PDSB) Gets a Buy From Oppenheimer
Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB) and Acurx Pharmaceuticals (ACXP)
Analysts Conflicted on These Healthcare Names: Accolade (ACCD), Arcturus Therapeutics (ARCT) and PDS Biotechnology (PDSB)
PDS Biotechnology Analyst Ratings
HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target
PDS Biotechnology Analyst Ratings
PDS Biotechnology (PDSB) Gets a Buy From H.C. Wainwright
PDS Biotechnology (PDSB) Gets a Buy From Noble Financial
Analysis
Price Target
No Data
